1092P Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma: 3-year subgroup analyses from RELATIVITY-047

Autor: Schadendorf, D., Tawbi, H.A., Hodi, F.S., Lipson, E.J., Ascierto, P.A., Medina Soto, F.A., Maio, M., Hernberg, M., Mackiewicz, J., Prey, S., Mujika Eizmendi, M.K., Atkinson, V.G., Hassel, J.C., Cinat, G., Keidel, S., Rodriguez, S., Wang, P.T., Dolfi, S., Long, G.V.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S723-S724

Viral molecular mimicry influences the antitumor immune response in murine and human melanoma

Autor: Chiaro J., Kasanen H. H. E., Whalley T., Capasso C., Gronholm M., Feola S., Peltonen K., Hamdan F., Hernberg M., Makela S., Karhapaa H., Brown P. E., Martins B., Fusciello M., Ylosmaki E. O., Greco D., Kreutzman A. S., Mustjoki S., Szomolay B., Cerullo V.

Molecular mimicry is one of the leading mechanisms by which infectious agents can induce autoimmunity. Whether a similar mechanism triggers an antitumor immune response is unexplored, and the role of antiviral T cells infiltrating the tumor has remai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3730::a229c4f24ebaa34a87cd726e40551f1d
http://hdl.handle.net/11588/879829

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Autor: Bottomley, A., Coens, C., Mierzynska, J., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., Sandhu, S., Puig, S., Ascierto, P. A., Larkin, J., Lorigan, P. C., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Di Giacomo, A. M., van den Eertwegh, A. J. M., Grob, J. -J., Gutzmer, R., Jamal, R., van Akkooi, A. C. J., Krepler, C., Ibrahim, N., Marreaud, S., Kicinski, M., Suciu, S., Robert, C., Eggermont, A. M. M., EORTC Melanoma Group, Lesimple, T., Maio, M., Linette, G., Mortier, L., Svane, I. M., Schachter, J., Brown, M., Hersey, P., Barrow, C., Kudchadkar, R., Dutriaux, C., Song, X., Quaglino, P., Queirolo, P., Meier, F., Stroyakovskiy, D., Guillot, B., Romero, P. L. O., Bastholt, L., Garbe, C., Grange, F., Mohr, P., Algazi, A., Bechter, O., Hernberg, M., Loquai, C., Meiss, F., Chiarion Sileni, V., Bar-Sela, G., Fitzharris, B., Saiag, P., Arnault, J. -P., Simon, J. -C., Stephens, R., Baurain, J. -F., Lebbe, C., Combemale, P., Dummer, R., Hauschild, A., Parente, P., Yamazaki, N., Milhem, M., Leccia, M. -T., Geoffrois, L., Kretschmer, L., Dunwoodie, E., Walker, J., Lotem, M., Hendler, D., Mackiewicz, A., Sekulovic, L., Dzienis, M., Hospers, G. A. P., Siano, M., Hassel, J., Corrie, P., Passos, M. -J., Levin, M., Hoeller, C., Machet, L., Hallmeyer, S., Waterston, A., Descamps, V., Kiecker, F., Aarts, M., Schmidt, H., Raimundo, A., Nyakas, M., Lacour, J. -P., Berking, C., Ferrucci, P. F., Jameson, M., Kim, K., Yokota, K., Kerger, J., Aubin, F., Groenewegen, G., Kapiteijn, H., Boehncke, W. -H., Utikal, J., Casasola, R., Marshall, E., Ferraresi, V., Richtig, E., Matkovic, S., Inozume, T., Crook, T., Mcneil, C., Kiyohara, Y., Avril, M. -F., Hein, R., Terheyden, P., Nathan, P., Aoi, J., Skytta, T., Jouary, T., Takenouchi, T., Straume, O., Martins, C., Mukhametshina, G.

Publikováno v: Lancet. Oncology, Vol. 22, No 5 (2021) pp. 655-664
EORTC Melanoma Group 2021, ' Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial ', The Lancet Oncology, vol. 22, no. 5, pp. 655-664 . https://doi.org/10.1016/S1470-2045(21)00081-4
Lancet Oncology, 22, 5, pp. 655-664
The Lancet Oncology, 22(5), 655-664. Lancet Publishing Group
Lancet Oncology, 22, 655-664
Lancet Oncology
Lancet Oncology, 2021, 22 (5), pp.655-664. ⟨10.1016/S1470-2045(21)00081-4⟩
The Lancet Oncology, 22(5), 655-664. ELSEVIER SCIENCE INC

Background: The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 trial in patients with resected, high-risk stage III melanoma demonstrated improved recurrence-free survival with adjuvant pembrolizumab compared w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80dc0ff7069bff303dade337b8effb2d
https://archive-ouverte.unige.ch/unige:159804

BRAF mutational status as a prognostic marker for survival in malignant melanoma:a systematic review and meta-analysis

Autor: Ny, L. (L.), Hernberg, M. (M.), Nyakas, M. (M.), Koivunen, J. (J.), Oddershede, L. (L.), Yoon, M. (M.), Wang, X. (X.), Guyot, P. (P.), Geisler, J. (J.)

Background: The analysis of the BRAF mutational status has been established as a standard procedure during diagnosis of advanced malignant melanoma due to the fact that BRAF inhibitors constitute a cornerstone in the treatment of metastatic disease.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2423::8596158f8fa13920a03425daad0b56d0
http://urn.fi/urn:nbn:fi-fe2020120299034

PO-1554 Degraded 4 MeV electron beam in treating basal cell carcinoma: Safety study

Autor: Valve, A., Koskenmies, S., Anttonen, A., Nurmi, H., Hernberg, M., Tenhunen, M.

Publikováno v: In Radiotherapy and Oncology May 2023 182 Supplement 1:S1261-S1261